Bixiye
QP33-21 Commercial Pharmacy Benefit Update – New Drug-Related Step Therapy (ST) Criteria: Winlevi®
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 28, 2021
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2301 - 2310 ee natiijooyinka 3289
Bixiye
QP28-21 Commercial Pharmacy Benefit Exclusion for Select Medications and Formulary Alternatives
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP25-21 Reminders Related to the Submission of Prior Authorizations and Subsequent Claims
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP32-21 Reminder: New Claim Edits For Professional Lab Claims Missing Required Data
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP27-21 MHCP Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP24-21 Commercial Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective June 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP26-21 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP30-21 Reference Guides for Commercial Networks and Medicare Products
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP29-21 Commercial and MHCP Pharmacy Benefit Update – Growth Hormone Notification
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021
Bixiye
QP31-21 Update for New to Market Medical Drugs: Avalglucosidase Alfa and Selexipag (Uptravi intravenous formulation)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 14, 2021